Indoramin in the treatment of hypertension: a placebo controlled trial.
The effect of the alpha-blocker indoramin was studied in a 4-week double-blind comparative trial with placebo in 39 patients with mild to moderate essential hypertension. Dosage of indoramin was individually adjusted and ranged from 125 mg to 200 mg daily. Indoramin produced a significantly greater reduction in diastolic blood pressure than placebo, and 9 (56%) out of 16 patients attained diastolic pressures of 90 mmHg or less. Heart rate, haematology and blood biochemistry were unaffected by treatment with indoramin, and there were no E.C.G. changes. Nine out of 19 patients on indoramin complained of side-effects. These were generally not troublesome, although 3 patients withdrew because of severe tiredness or weight gain.